Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.65 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.59 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185966 | 1.00 | S1PR1 (0.67) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL11845832 | 1.00 | S1PR1 (0.67) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL9663932 | 1.00 | S1PR1 (0.67) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL8080040 | 0.98 | FFAR1 (0.68) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL9663920 | 0.97 | LMNA (0.69) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL8001563 | 0.97 | LMNA (0.69) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL7995339 | 0.97 | LMNA (0.69) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL9259693 | 0.96 | S1PR1 (0.62) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL25175626 | 0.95 | S1PR1 (0.68) | S1PR1S1PR3S1PR4FFAR1LMNA | |
| SCHEMBL11309024 | 0.95 | S1PR1 (0.68) | S1PR1S1PR3S1PR4FFAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343306-B1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN PRESIDENT NAT CT NEUROLOGY & PSYCHIATRY (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2343306-A1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20060074235-A1 | Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1619199-A1 | GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | S1PR1 12/4885S1PR3 9/4885S1PR4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.